Gaucher Disease — Deal Benchmarks & Valuation
Market Analysis
Gaucher Disease is one of the most actively transacted indications in metabolic licensing. Phase 2 deals for gaucher disease carry a median total deal value of $3.0B, with upfront payments ranging from $351M to $917M. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones.
Milestone structures for gaucher disease deals allocate $431M to development milestones, $526M to regulatory milestones, and $1.4B to commercial milestones. Royalty rates range from 14.3% to 26.2% at the base tier, with tiered escalation reaching 18.3%-30.2% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for gaucher disease licensing?
What royalty rates are standard for gaucher disease deals?
How are gaucher disease deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.